Last updated on March 2019

Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers

Brief description of study

The purpose of this study is to test the safety of combining the drugs osimertinib and bevacizumab at different dose levels. The investigators want to find out what effects, good and/or bad, taking osimertinib and bevacizumab has on the patient and lung cancer. This study will try to find the best dose of osimertinib and bevacizumab given together that does not cause significant side effects. Once the investigators determine that combining osimertinib and bevacizumab is safe, they want to see if the combination is effective in treating lung cancers with the EGFR mutation.

Clinical Study Identifier: NCT02803203

Contact Investigators or Research Sites near you

Start Over

Helena Yu, MD

Memorial Sloan Kettering at Mercy Medical Center
Rockville Centre, NY United States

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.